{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:01Z","timestamp":1781643421890,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUBK.C220.24.081"],"award-info":[{"award-number":["SUBK.C220.24.081"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2024\/53\/N\/NZ3\/01093"],"award-info":[{"award-number":["UMO-2024\/53\/N\/NZ3\/01093"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"publisher","award":["P30 CA 138313"],"award-info":[{"award-number":["P30 CA 138313"]}],"id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is a growing interest in the role of sphingolipids in the background of multiple sclerosis (MS). The goal of this study was to evaluate the serum levels of antibodies against ceramide-1-phosphate (C1P) subclasses and their relationships with clinical status in MS. The study groups comprised 39 patients with relapsing-remitting MS (RRMS), 26 patients with other neurological diseases (OND) and 12 healthy subjects (HS). Anti-C1P IgG levels in serum were determined using ELISA test. Levels of anti-C18:0-C1P and anti-C24:1-C1P IgG were significantly increased (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001, respectively) in RRMS compared to HS, while anti-C16:0-C1P and anti-C24:0-C1P IgG \u2013 significantly lower\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001 in RRMS compared to OND, with large effect size (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009\u2265\u20090.5) in all above cases. In both settings the acceptable discriminatory performance for RRMS subtype from HS (AUC\u2009=\u200978.1%, 95% CI 66.1\u201390.4 and AUC\u2009=\u200976.9%, 95% CI 60.3\u201393.6, respectively) as well as from OND (AUC\u2009=\u200979.8%, 95% CI 68.2\u201391.4 and AUC\u2009=\u200994.2%, 95% CI 88.6\u201399.8, accordingly) by receiver operating curve (ROC) was shown. Validation of ROC by cluster analysis confirmed the ability of these anti-C1P IgG panels to discriminate between the study groups. No relationships were found between levels of antibodies in the anti-C1P IgG panel in RRMS group and disease duration, degree of disability or Link index. These findings highlight the relevant role of C1P as a target and\/or mediator of autoimmune response in MS and potential value of anti-C1P antibodies as biomarkers in differential diagnosis of this disease.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-43823-y","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:35:17Z","timestamp":1773927317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A potential of serum anti-C1P IgG antibodies as biomarkers in differential diagnosis of relapsing-remitting multiple sclerosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Justyna","family":"Chojdak-Lukasiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jakubiak-Augustyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdzislaw M.","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Gubernator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Blazej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pokryszko-Dragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Budrewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Podbielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"43823_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson, R. & Giovannoni, G. Multiple sclerosis - a review. Eur. J. Neurol. 26, 27\u201340. https:\/\/doi.org\/10.1111\/ene.13819 (2019).","journal-title":"Eur. J. Neurol."},{"key":"43823_CR2","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann, H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front. Immunol. 9, 3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116 (2018).","journal-title":"Front. Immunol."},{"key":"43823_CR3","doi-asserted-by":"publisher","unstructured":"Ciubotaru, A. et al. Neurodegenerative Biomarkers in Multiple Sclerosis: At the Interface Between Research and Clinical Practice. Diagnostics (Basel). 15 https:\/\/doi.org\/10.3390\/diagnostics15091178 (2025).","DOI":"10.3390\/diagnostics15091178"},{"key":"43823_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/metabo14100545","volume":"14","author":"P Pousinis","year":"2024","unstructured":"Pousinis, P. et al. Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis. Metabolites 14, 545 (2024).","journal-title":"Metabolites"},{"key":"43823_CR5","doi-asserted-by":"publisher","unstructured":"Smusz, J. et al. Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives-A Systematic Review. Int. J. Mol. Sci. 26 https:\/\/doi.org\/10.3390\/ijms26189207 (2025).","DOI":"10.3390\/ijms26189207"},{"key":"43823_CR6","doi-asserted-by":"publisher","unstructured":"Lattau, S. S. J. et al. Plasma Lipidomic Profiling Using Mass Spectrometry for Multiple Sclerosis Diagnosis and Disease Activity Stratification (LipidMS). Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms25052483 (2024).","DOI":"10.3390\/ijms25052483"},{"key":"43823_CR7","doi-asserted-by":"publisher","first-page":"15644","DOI":"10.1038\/s41598-020-72654-8","volume":"10","author":"M Amatruda","year":"2020","unstructured":"Amatruda, M. et al. Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration. Sci. Rep. 10, 15644. https:\/\/doi.org\/10.1038\/s41598-020-72654-8 (2020).","journal-title":"Sci. Rep."},{"key":"43823_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ncl.2023.06.008","volume":"42","author":"A Chertcoff","year":"2024","unstructured":"Chertcoff, A., Schneider, R., Azevedo, C. J., Sicotte, N. & Oh, J. Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis. Neurol. Clin. 42, 15\u201338. https:\/\/doi.org\/10.1016\/j.ncl.2023.06.008 (2024).","journal-title":"Neurol. Clin."},{"key":"43823_CR9","doi-asserted-by":"publisher","unstructured":"Podbielska, M., O\u2019Keeffe, J. & Pokryszko-Dragan, A. New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22147319 (2021).","DOI":"10.3390\/ijms22147319"},{"key":"43823_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11011-025-01778-5","volume":"41","author":"AM Qadir","year":"2026","unstructured":"Qadir, A. M., Omar, R. A., Sulaiman, S. H. & Barzani, H. A. H. Brain lipid metabolism and transport: implications for neurodegeneration and therapeutic strategies: a comprehensive review. Metab. Brain Dis. 41, 14. https:\/\/doi.org\/10.1007\/s11011-025-01778-5 (2026).","journal-title":"Metab. Brain Dis."},{"key":"43823_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1093\/brain\/awu139","volume":"137","author":"OG Vidaurre","year":"2014","unstructured":"Vidaurre, O. G. et al. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 137, 2271\u20132286. https:\/\/doi.org\/10.1093\/brain\/awu139 (2014).","journal-title":"Brain"},{"key":"43823_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/1352458514561908","volume":"21","author":"A Checa","year":"2015","unstructured":"Checa, A. et al. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Mult Scler. 21, 1271\u20131279. https:\/\/doi.org\/10.1177\/1352458514561908 (2015).","journal-title":"Mult Scler."},{"key":"43823_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1177\/1352458520971816","volume":"27","author":"AG Filippatou","year":"2021","unstructured":"Filippatou, A. G. et al. Serum ceramide levels are altered in multiple sclerosis. Mult Scler. 27, 1506\u20131519. https:\/\/doi.org\/10.1177\/1352458520971816 (2021).","journal-title":"Mult Scler."},{"key":"43823_CR14","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1042\/CS20180506","volume":"132","author":"J Kurz","year":"2018","unstructured":"Kurz, J. et al. The relevance of ceramides and their synthesizing enzymes for multiple sclerosis. Clin. Sci. (Lond). 132, 1963\u20131976. https:\/\/doi.org\/10.1042\/CS20180506 (2018).","journal-title":"Clin. Sci. (Lond)"},{"key":"43823_CR15","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1194\/jlr.M070664","volume":"57","author":"M Podbielska","year":"2016","unstructured":"Podbielska, M. et al. Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J. Lipid Res. 57, 2028\u20132039. https:\/\/doi.org\/10.1194\/jlr.M070664 (2016).","journal-title":"J. Lipid Res."},{"key":"43823_CR16","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1194\/jlr.RA120001022","volume":"61","author":"M Podbielska","year":"2020","unstructured":"Podbielska, M. et al. Distinctive sphingolipid patterns in chronic multiple sclerosis lesions. J. Lipid Res. 61, 1464\u20131479. https:\/\/doi.org\/10.1194\/jlr.RA120001022 (2020).","journal-title":"J. Lipid Res."},{"key":"43823_CR17","doi-asserted-by":"publisher","first-page":"104565","DOI":"10.1016\/j.msard.2023.104565","volume":"71","author":"M Podbielska","year":"2023","unstructured":"Podbielska, M. et al. Ceramide is implicated in humoral peripheral and intrathecal autoimmune response in MS patients. Mult Scler. Relat. Disord. 71, 104565. https:\/\/doi.org\/10.1016\/j.msard.2023.104565 (2023).","journal-title":"Mult Scler. Relat. Disord"},{"key":"43823_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","author":"AJ Thompson","year":"2017","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2 (2017).","journal-title":"Lancet Neurol."},{"key":"43823_CR19","doi-asserted-by":"publisher","first-page":"7821","DOI":"10.1016\/S0040-4039(00)01361-7","volume":"41","author":"ZM Szulc","year":"2000","unstructured":"Szulc, Z. M., Hannun, Y. A. & Bielawska, A. A facile regioselective synthesis of sphingosine 1-phosphate and ceramide 1-phosphate. Tetrahedron Lett. 41, 7821\u20137824. https:\/\/doi.org\/10.1016\/S0040-4039(00)01361-7 (2000).","journal-title":"Tetrahedron Lett."},{"key":"43823_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1194\/jlr.M001396","volume":"51","author":"M Podbielska","year":"2010","unstructured":"Podbielska, M. et al. Novel myelin penta- and hexa-acetyl-galactosyl-ceramides: structural characterization and immunoreactivity in cerebrospinal fluid. J. Lipid Res. 51, 1394\u20131406. https:\/\/doi.org\/10.1194\/jlr.M001396 (2010).","journal-title":"J. Lipid Res."},{"key":"43823_CR21","unstructured":"Kassambara, A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package version 0.7.2, (2023). https:\/\/rpkgs.datanovia.com\/rstatix\/"},{"key":"43823_CR22","doi-asserted-by":"crossref","unstructured":"Rappoport, A. in The Science of the Brain (ed Ari Rappoport) 161\u2013176 Academic Press, (2025).","DOI":"10.1016\/B978-0-44-345008-2.00014-X"},{"key":"43823_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/1352458509106708","volume":"15","author":"M Podbielska","year":"2009","unstructured":"Podbielska, M. & Hogan, E. L. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult Scler. 15, 1011\u20131029. https:\/\/doi.org\/10.1177\/1352458509106708 (2009).","journal-title":"Mult Scler."},{"key":"43823_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1750-3639.2011.00501.x","volume":"22","author":"S Kim","year":"2012","unstructured":"Kim, S., Steelman, A. J., Zhang, Y., Kinney, H. C. & Li, J. Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol. 22, 41\u201357. https:\/\/doi.org\/10.1111\/j.1750-3639.2011.00501.x (2012).","journal-title":"Brain Pathol."},{"key":"43823_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000484621","volume":"25","author":"KA Becker","year":"2017","unstructured":"Becker, K. A. et al. Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase\/Ceramide System. Neuro-Signals 25, 88\u201397. https:\/\/doi.org\/10.1159\/000484621 (2017).","journal-title":"Neuro-Signals"},{"key":"43823_CR26","doi-asserted-by":"publisher","unstructured":"Alexandropoulou, I. et al. Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment. Nutrients 15 https:\/\/doi.org\/10.3390\/nu15010229 (2023).","DOI":"10.3390\/nu15010229"},{"key":"43823_CR27","doi-asserted-by":"publisher","unstructured":"Custodia, A. et al. Ceramide\/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer\u2019s Disease and Other Neurodegenerative Diseases. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms23158082 (2022).","DOI":"10.3390\/ijms23158082"},{"key":"43823_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf093","author":"R Klingenberg","year":"2025","unstructured":"Klingenberg, R. et al. Ceramides in cardiovascular disease - emerging role as independent risk predictors and novel therapeutic targets. Cardiovascular. Res. https:\/\/doi.org\/10.1093\/cvr\/cvaf093 (2025).","journal-title":"Cardiovascular. Res."},{"key":"43823_CR29","doi-asserted-by":"publisher","first-page":"109980","DOI":"10.1016\/j.cellsig.2021.109980","volume":"83","author":"A Gomez-Larrauri","year":"2021","unstructured":"Gomez-Larrauri, A., Ouro, A., Trueba, M. & Gomez-Munoz, A. Regulation of cell growth, survival and migration by ceramide 1-phosphate - implications in lung cancer progression and inflammation. Cell. Signal. 83, 109980. https:\/\/doi.org\/10.1016\/j.cellsig.2021.109980 (2021).","journal-title":"Cell. Signal."},{"key":"43823_CR30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bcp.2005.12.027","volume":"71","author":"H Nakamura","year":"2006","unstructured":"Nakamura, H., Hirabayashi, T., Shimizu, M. & Murayama, T. Ceramide-1-phosphate activates cytosolic phospholipase A2alpha directly and by PKC pathway. Biochem. Pharmacol. 71, 850\u2013857. https:\/\/doi.org\/10.1016\/j.bcp.2005.12.027 (2006).","journal-title":"Biochem. Pharmacol."},{"key":"43823_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2796.2008.02035.x","volume":"265","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J. Intern. Med. 265, 459\u2013464. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.02035.x (2009).","journal-title":"J. Intern. Med."},{"key":"43823_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0022-510X(84)90085-6","volume":"65","author":"JH DuBois","year":"1984","unstructured":"DuBois, J. H. & Cuzner, M. L. Regulation of lymphocyte activation by PGE2 in multiple sclerosis. J. Neurol. Sci. 65, 211\u2013219. https:\/\/doi.org\/10.1016\/0022-510X(84)90085-6 (1984).","journal-title":"J. Neurol. Sci."},{"key":"43823_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00401-025-02878-3","volume":"149","author":"CE Hansen","year":"2025","unstructured":"Hansen, C. E. et al. Spatial mapping of the AA-PGE2-EP axis in multiple sclerosis lesions. Acta Neuropathol. 149, 39. https:\/\/doi.org\/10.1007\/s00401-025-02878-3 (2025).","journal-title":"Acta Neuropathol."},{"key":"43823_CR34","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/wnl.36.12.1587","volume":"36","author":"P Dore-Duffy","year":"1986","unstructured":"Dore-Duffy, P., Donaldson, J. O., Koff, T., Longo, M. & Perry, W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 36, 1587\u20131590. https:\/\/doi.org\/10.1212\/wnl.36.12.1587 (1986).","journal-title":"Neurology"},{"key":"43823_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2174\/1871527319666200825164123","volume":"21","author":"M Hoxha","year":"2022","unstructured":"Hoxha, M., Spahiu, E., Prendi, E. & Zappacosta, B. A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis. CNS Neurol. Disord. Drug Target. 21, 160\u2013187. https:\/\/doi.org\/10.2174\/1871527319666200825164123 (2022).","journal-title":"CNS Neurol. Disord. Drug Target"},{"key":"43823_CR36","doi-asserted-by":"publisher","first-page":"17570","DOI":"10.1074\/jbc.M312885200","volume":"279","author":"S Mitsutake","year":"2004","unstructured":"Mitsutake, S. et al. Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells. J. Biol. Chem. 279, 17570\u201317577. https:\/\/doi.org\/10.1074\/jbc.M312885200 (2004).","journal-title":"J. Biol. Chem."},{"key":"43823_CR37","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.4049\/jimmunol.1402681","volume":"196","author":"K Baudiss","year":"2016","unstructured":"Baudiss, K. et al. C1P Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-kappaB Activation in Neutrophils. J. Immunol. 196, 2319\u20132326. https:\/\/doi.org\/10.4049\/jimmunol.1402681 (2016).","journal-title":"J. Immunol."},{"key":"43823_CR38","doi-asserted-by":"publisher","first-page":"E1213","DOI":"10.1152\/ajpendo.00480.2012","volume":"304","author":"L Arana","year":"2013","unstructured":"Arana, L. et al. Ceramide 1-phosphate induces macrophage chemoattractant protein-1 release: involvement in ceramide 1-phosphate-stimulated cell migration. Am. J. Physiol. Endocrinol. Metab. 304, E1213\u20131226. https:\/\/doi.org\/10.1152\/ajpendo.00480.2012 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"43823_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/mol.116.107169","volume":"91","author":"EV Mesev","year":"2017","unstructured":"Mesev, E. V., Miller, D. S. & Cannon, R. E. Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling. Mol. Pharmacol. 91, 373\u2013382. https:\/\/doi.org\/10.1124\/mol.116.107169 (2017).","journal-title":"Mol. Pharmacol."},{"key":"43823_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbalip.2009.01.023","volume":"1791","author":"MH Granado","year":"2009","unstructured":"Granado, M. H., Gangoiti, P., Ouro, A., Arana, L. & Gomez-Munoz, A. Ceramide 1-phosphate inhibits serine palmitoyltransferase and blocks apoptosis in alveolar macrophages. Biochim. Biophys. Acta. 1791, 263\u2013272. https:\/\/doi.org\/10.1016\/j.bbalip.2009.01.023 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"43823_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1194\/jlr.M300158-JLR200","volume":"45","author":"A Gomez-Munoz","year":"2004","unstructured":"Gomez-Munoz, A., Kong, J. Y., Salh, B. & Steinbrecher, U. P. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J. Lipid Res. 45, 99\u2013105. https:\/\/doi.org\/10.1194\/jlr.M300158-JLR200 (2004).","journal-title":"J. Lipid Res."},{"key":"43823_CR42","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1038\/s41598-021-87795-7","volume":"11","author":"F Al-Rashed","year":"2021","unstructured":"Al-Rashed, F. et al. Ceramide kinase regulates TNF-\u03b1-induced immune responses in human monocytic cells. Sci. Rep-Uk. 11, 8259. https:\/\/doi.org\/10.1038\/s41598-021-87795-7 (2021).","journal-title":"Sci. Rep-Uk"},{"key":"43823_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JAD-2011-111202","volume":"29","author":"V Filippov","year":"2012","unstructured":"Filippov, V. et al. Increased ceramide in brains with Alzheimer\u2019s and other neurodegenerative diseases. J. Alzheimers Dis. 29, 537\u2013547. https:\/\/doi.org\/10.3233\/JAD-2011-111202 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"43823_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-012-1014-4","volume":"124","author":"R van Doorn","year":"2012","unstructured":"van Doorn, R. et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 124, 397\u2013410. https:\/\/doi.org\/10.1007\/s00401-012-1014-4 (2012).","journal-title":"Acta Neuropathol."},{"key":"43823_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molmed.2018.10.009","volume":"25","author":"J Kurz","year":"2019","unstructured":"Kurz, J., Parnham, M. J., Geisslinger, G. & Schiffmann, S. Ceramides as Novel Disease Biomarkers. Trends Mol. Med. 25, 20\u201332. https:\/\/doi.org\/10.1016\/j.molmed.2018.10.009 (2019).","journal-title":"Trends Mol. Med."},{"key":"43823_CR46","doi-asserted-by":"publisher","unstructured":"Farooqui, A. A., Farooqui, T. & Phospholipids Sphingolipids, and Cholesterol-Derived Lipid Mediators and Their Role in Neurological Disorders. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms251910672 (2024).","DOI":"10.3390\/ijms251910672"},{"key":"43823_CR47","doi-asserted-by":"publisher","unstructured":"Uranbileg, B. et al. Alzheimer\u2019s disease manifests abnormal sphingolipid metabolism. Front. Aging Neurosci. 16 https:\/\/doi.org\/10.3389\/fnagi.2024.1368839 (2024).","DOI":"10.3389\/fnagi.2024.1368839"},{"key":"43823_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.plipres.2015.09.002","volume":"61","author":"A Gomez-Munoz","year":"2016","unstructured":"Gomez-Munoz, A. et al. Control of inflammatory responses by ceramide, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res. 61, 51\u201362. https:\/\/doi.org\/10.1016\/j.plipres.2015.09.002 (2016).","journal-title":"Prog Lipid Res."},{"key":"43823_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.bbalip.2016.02.007","volume":"1861","author":"N Presa","year":"2016","unstructured":"Presa, N. et al. Regulation of cell migration and inflammation by ceramide 1-phosphate. Biochim. Biophys. Acta. 1861, 402\u2013409. https:\/\/doi.org\/10.1016\/j.bbalip.2016.02.007 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"43823_CR50","doi-asserted-by":"publisher","first-page":"137ra173","DOI":"10.1126\/scitranslmed.3003831","volume":"4","author":"PP Ho","year":"2012","unstructured":"Ho, P. P. et al. Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci. Transl Med. 4, 137ra173. https:\/\/doi.org\/10.1126\/scitranslmed.3003831 (2012).","journal-title":"Sci. Transl Med."},{"key":"43823_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3389\/fimmu.2015.00565","volume":"6","author":"K Blauth","year":"2015","unstructured":"Blauth, K., Owens, G. P. & Bennett, J. L. The Ins and Outs of B Cells in Multiple Sclerosis. Front. Immunol. 6, 565. https:\/\/doi.org\/10.3389\/fimmu.2015.00565 (2015).","journal-title":"Front. Immunol."},{"key":"43823_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jneuroim.2012.01.002","volume":"248","author":"FJ Quintana","year":"2012","unstructured":"Quintana, F. J., Yeste, A., Weiner, H. L. & Covacu, R. Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J. Neuroimmunol. 248, 53\u201357. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.01.002 (2012).","journal-title":"J. Neuroimmunol."},{"key":"43823_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbamem.2005.02.014","volume":"1711","author":"J Sot","year":"2005","unstructured":"Sot, J., Goni, F. M. & Alonso, A. Molecular associations and surface-active properties of short- and long-N-acyl chain ceramides. Biochim. Biophys. Acta. 1711, 12\u201319. https:\/\/doi.org\/10.1016\/j.bbamem.2005.02.014 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"43823_CR54","doi-asserted-by":"publisher","first-page":"159092","DOI":"10.1016\/j.bbalip.2021.159092","volume":"1867","author":"T Mutoh","year":"2022","unstructured":"Mutoh, T. et al. Species-specific accumulation of ceramides in cerebrospinal fluid from encephalomyeloradiculoneurpathy patients associated with peripheral complement activation: A pilot study. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids. 1867, 159092. https:\/\/doi.org\/10.1016\/j.bbalip.2021.159092 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"43823_CR55","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s11064-012-0728-y","volume":"37","author":"M Podbielska","year":"2012","unstructured":"Podbielska, M., Krotkiewski, H. & Hogan, E. L. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. Neurochem Res. 37, 1154\u20131169. https:\/\/doi.org\/10.1007\/s11064-012-0728-y (2012).","journal-title":"Neurochem Res."},{"key":"43823_CR56","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1194\/jlr.D008532","volume":"51","author":"SM Hammad","year":"2010","unstructured":"Hammad, S. M. et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. 51, 3074\u20133087. https:\/\/doi.org\/10.1194\/jlr.D008532 (2010).","journal-title":"J. Lipid Res."},{"key":"43823_CR57","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3855\/jidc.513","volume":"4","author":"K Singh","year":"2010","unstructured":"Singh, K., Singh, B. & Ray, P. Anti-ceramide antibodies in leprosy: marker for nerve damage? J. Infect. Dev. Ctries. 4, 378\u2013381 (2010).","journal-title":"J. Infect. Dev. Ctries."},{"key":"43823_CR58","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3389\/fimmu.2017.01386","volume":"8","author":"A Saroha","year":"2017","unstructured":"Saroha, A. et al. Critical Role for Very-Long Chain Sphingolipids in Invariant Natural Killer T Cell Development and Homeostasis. Front. Immunol. 8, 1386. https:\/\/doi.org\/10.3389\/fimmu.2017.01386 (2017).","journal-title":"Front. Immunol."},{"key":"43823_CR59","doi-asserted-by":"publisher","first-page":"1611929","DOI":"10.3389\/pore.2024.1611929","volume":"30","author":"L Budi","year":"2024","unstructured":"Budi, L. et al. Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer. Pathol. Oncol. Res. 30, 1611929. https:\/\/doi.org\/10.3389\/pore.2024.1611929 (2024).","journal-title":"Pathol. Oncol. Res."},{"key":"43823_CR60","doi-asserted-by":"publisher","first-page":"e0186842","DOI":"10.1371\/journal.pone.0186842","volume":"12","author":"C Beseler","year":"2017","unstructured":"Beseler, C., Vollmer, T., Graner, M. & Yu, X. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution. PloS one. 12, e0186842. https:\/\/doi.org\/10.1371\/journal.pone.0186842 (2017).","journal-title":"PloS one"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43823-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43823-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43823-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:29:54Z","timestamp":1781641794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43823-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43823"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43823-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7825469\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9437"}}